We are very excited to announce that
Prof. Ranjeny Thomas' research and development
of a potential treatment for rheumatoid arthritis
has reached a very important milestone.

The human trial phase of the drug candidate known as DEN-181 has commenced, with the first patient being given the treatment.
 

This is significant progress. This first clinical trial will provide the bridge that will bring the scientific data into clinical development and hopefully into clinical practice. Initial results of the trial are expected in late 2018.

DEN-181 is a vaccine-style treatment, or "immunotherapy", which has been designed specifically for people who test positively for the most common form of rheumatoid arthritis, known as anti-CCP.

This treatment is a nanoparticle-based immunotherapy designed to regulate the immune cells that cause inflammation, pain and joint damage in rheumatoid arthritis. It is designed to re-educate the body's immune system, and therefore target the underlying cause of the disease rather than treat the inflammation associated with rheumatoid arthritis like the drugs currently available.

This milestone is the result of over 20 years of research.   Arthritis Queensland's donors have played an important role in supporting Prof. Ranjeny Thomas' research throughout those years - thank you so much for your continued support.

Further details of this first clinical study including patient eligibility criteria are available at  www.anzctr.com using ‘Dendright’ as the search term.

At Arthritis Queensland we are determined to improve the lives of Queenslanders living with arthritis.
The results of this trial could be life-changing for future generations of people not only here but around the world.

We congratulate Prof. Ranjeny Thomas and her team on reaching this incredible milestone.

We look forward to keeping you updated as the trials progress.